2027

Medicare Drug Price Negotiation Program

The Inflation Reduction Act (IRA), passed in 2022, authorizes Medicare to directly negotiate prices for select high-cost prescription drugs for the first time. Annually starting in 2026, the Centers for Medicare & Medicaid Services (CMS) will select the top Part D drugs based on cost and utilization for negotiations. The MFP represents the highest amount a Medicare Part D beneficiary can be charged for a negotiated drug.

Why is this important? The new prices could help reduce beneficiaries' out-of-pocket drug spending.

What is changing in 2027? Fifteen additional drugs were added for negotiation and four drugs were removed (Stelara, Xarelto, Entresto, Fiasp/Novolog).

2027 Negotiated Drug Prices

Members typically pay less out-of-pocket due to plan benefits like copays or coinsurance, which vary based on the drug tier and the member's current coverage phase, such as whether the deductible has been met.

Note: List price is the initial price set by the manufacturer before any discounts, rebates, or insurance adjustments are applied. The quoted prices are for a 30-day supply.

MFP Drugs Added for 2027

Drug Name	Condition(s) Treated	2024 List Price	2027 List Price	Discount
Ozempic; Wegovy	Diabetes, Heart Disease	$959	$274	71%
Trelegy Ellipta	Asthma; Chronic obstructive pulmonary disease	$654	$175	73%
Xtandi	Prostate cancer	$13,480	$7,004	48%
Pomalyst	Kaposi sarcoma; Multiple myeloma	$21,744	$8,650	60%
Ofev	Idiopathic pulmonary fibrosis	$12,622	$6,350	50%
Ibrance	Breast cancer	$15,741	$7,871	50%
Linzess	Chronic idiopathic constipation; Irritable bowel syndrome with constipation	$539	$136	75%
Calquence	Leukemia, Lymphoma	$14,228	$8,600	40%
Austedo; Austedo XR	Movement disorder	$6,623	$4,093	38%
Breo Ellipta	Asthma; Chronic obstructive pulmonary disease	$397	$67	83%
Xifaxan	Hepatic encephalopathy; Irritable bowel syndrome with diarrhea	$2,696	$1,000	63%
Vraylar	Bipolar I disorder; Depression; Schizophrenia	$1,376	$770	44%
Tradjenta	Diabetes	$488	$78	84%
Janumet; Janumet XR	Diabetes	$526	$80	85%
Otezla; Otezla XR	Oral ulcers in Behcet's Disease; Plaque psoriasis; Psoriatic arthritis	$4,722	$1,650	65%

Refer to the Evidence of Coverage for plan details.

WC_12834

Scan to visit the Florida Pharmacy Resources page

MFP Drugs Continuing in 2027				
Drug Name	**Condition(s) Treated**	**2023 List Price**	**2027 List Price**	**Discount**
Januvia	Diabetes	$527	$116	79%
Farxiga	Diabetes, Heart Failure, Kidney Disease	$556	$183	68%
Jardiance	Diabetes, Heart Failure, Kidney Disease	$573	$202	66%
Enbrel	Arthritis, Psoriasis	$7,106	$2,419	67%
Eliquis	Blood Clots	$521	$237	56%
Imbruvica	Blood Cancer	$14,934	$9,571	38%

Future years

The negotiated prices stay in place as long as the drug is in the program. Each year, prices may go up based on inflation. Fifteen more drugs will be selected each year as a part of this program. For additional information, please refer to cms.gov.

Refer to the Evidence of Coverage for plan details.

Scan to visit the Florida Pharmacy Resources page